Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Podobné jednotky

• Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation
  Autor: Barrón, Feliciano, a další
  Vydáno: (2018)
• Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
  Autor: Bria, E., a další
  Vydáno: (2011)
• Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions
  Autor: Floc’h, Nicolas, a další
  Vydáno: (2018)
• Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
  Autor: Attili, Ilaria, a další
  Vydáno: (2020)
• Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
  Autor: Imamura, Fumio, a další
  Vydáno: (2020)